Alexion Pharmaceuticals Company Profile (NASDAQ:ALXN)

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

Alexion Pharmaceuticals declared that its Board of Directors has approved a stock repurchase plan on Sunday, April 9th 2017, which permits the company to repurchase $1,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to purchase up to 3.4% of its stock through open market purchases. Stock repurchase plans are often a sign that the company's management believes its shares are undervalued.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) posted its earnings results on Thursday, April, 27th. The company reported $1.38 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.05 by $0.33. The firm earned $870 million during the quarter, compared to analyst estimates of $826.63 million. Alexion Pharmaceuticals had a net margin of 14.52% and a return on equity of 11.72%. Alexion Pharmaceuticals's revenue for the quarter was up 24.3% on a year-over-year basis. During the same period last year, the company earned $1.11 EPS. View Alexion Pharmaceuticals' Earnings History.

Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, July, 27th 2017. View Earnings Estimates for Alexion Pharmaceuticals.

Alexion Pharmaceuticals issued an update on its FY17 earnings guidance on Thursday, April, 27th. The company provided earnings per share guidance of $5.10-5.30 for the period, compared to the Thomson Reuters consensus estimate of $5.25. The company issued revenue guidance of $3.4-3.5 billion, compared to the consensus revenue estimate of $3.47 billion.

23 analysts have issued 1 year price objectives for Alexion Pharmaceuticals' shares. Their predictions range from $120.00 to $221.00. On average, they anticipate Alexion Pharmaceuticals' stock price to reach $157.86 in the next twelve months. View Analyst Ratings for Alexion Pharmaceuticals.

Here are some recent quotes from research analysts about Alexion Pharmaceuticals stock:

• 1. Morgan Stanley analysts commented, "re-prioritize the strategic direction" of the company. Furthermore, the second-quarter strategic review serves as a "turning point" for investor sentiment."While we understand investor unease that another 'shoe could drop' on this story, we see the risk/reward as compelling and believe new management is making progress right sizing the company and refocusing its efforts," the analyst wrote.2. Underappreciated StoryHarrison also believes Alexion's stock is pricing "little-to-no value" for the ALXN1210 life-cycle extension strategy. Meanwhile, investors are under-appreciating the antibody but the sentiment could turn move positive with potential gMG approval and the release of pivotal data.Harrison also believes Alexion's core asset value is "not impaired." Also, the analyst suggested that the underlying patient need and use of Solaris is "sound" and the company's strategy to protect Solaris through new IP and ALXN1210 is "very defensible with clarity on this strategy coming in less than 12 months." (5/25/2017)
• 2. J P Morgan Chase & Co analysts commented, "Anavex announced positive preclinical data for 2-73 in several neurodevelopmental disorders: Angelman, Fragile X and Rett syndromes." (5/23/2017)
• 3. Barclays PLC analysts commented, "provides support to the patient association in Brazil in the form of unrestricted educational grants and in accordance with local laws and regulations and industry code." In addition, the spokesperson confirmed that Alexion has not been charged with any criminal or civil misconduct.Investors Shrug Barclays' CallShortly after reports of Alexion's raid on Monday, analysts at Barclays offered a quick take on how investors should react.Barclays' Geoff Meacham suggested that while the headline report looks "onerous," the report shouldn't be viewed as a major fundamental concern. The analyst cited "good Soliris growth" (5/9/2017)
• 4. Cowen and Company analysts commented, "We recently hosted investor meetings with CEO Ludwig Hantson, CFO Dave." (4/28/2017)
• 5. According to Zacks Investment Research, "Alexion's guidance for 2017 was tepid signaling the slowdown of sales. Sales of Soliris have weakened in recent quarters thereby dampening growth prospects. Soliris’ revenue growth will also be impacted by the enrollment ramp-up of trials on ALXN1210 (by $70 million - $110 million). The drug is also witnessing access challenges in Latin America. Additionally, Alexion has faced significant setbacks in its attempts to expand Soliris’ label. Moreover, ongoing focus on drug pricing and sudden departure of its key executives in the middle of an internal probe into the sales practices related to Soliris are concerning. The probe revealed a material weakness in Alexion’s internal controls over financial reporting. Shares of Alexion have underperformed the broader industry in the past one year. Estimates have reduced lately ahead of the Q1 earnings results. Alexion has a positive record of earnings surprises in recent quarters." (4/18/2017)

Some companies that are related to Alexion Pharmaceuticals include BioMarin Pharmaceutical (BMRN), Abcam Plc (ABC), Anika Therapeutics (ANIK), Myovant Sciences Ltd (MYOV), ChemoCentryx (CCXI), Syros Pharmaceuticals (SYRS), Sinovac Biotech (SVA), Syndax Pharmaceuticals (SNDX), Fortress Biotech (FBIO), Peregrine Pharmaceuticals (PPHM), Kamada (KMDA), Mereo BioPharma Group PLC (MPH), Kadmon Holdings (KDMN), MediWound (MDWD), Cardiome Pharma Corporation (CRME), VIVUS (VVUS), Strongbridge Biopharma PLC (SBBP) and Vericel Corporation (VCEL).

Alexion Pharmaceuticals' management team includes the folowing people:

• David R. Brennan, Chairman of the Board
• Ludwig N. Hantson Ph.D., Chief Executive Officer, Director
• David John Anderson, Chief Financial Officer
• John B. Moriarty J.D., Executive Vice President, General Counsel
• Martin Mackay Ph.D., Executive Vice President, Global Head - Research and Development
• Julie O'Neill, Executive Vice President - Global Operations
• Edward Miller J.D., Senior Vice President, Global Chief Compliance Officer
• Heidi L. Wagner J.D., Senior Vice President - Global Governmental Affairs
• Brian Goff, Chief Commercial Officer
• R. Douglas Norby, Lead Independent Director

Alexion Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Bank of Montreal Can (0.63%), State Treasurer State of Michigan (0.17%), National Pension Service (0.09%), Factory Mutual Insurance Co. (0.09%), Chevy Chase Trust Holdings Inc. (0.09%) and First Quadrant L P CA (0.08%). Company insiders that own Alexion Pharmaceuticals stock include Alvin S Parven, Ann M Veneman, Bros Advisors Lp Baker, Carsten Thiel, Clare Carmichael, David Hallal, Edward Miller, Heidi L Wagner, John B Moriarty, Julie O'neill, Leonard Bell, Ludwig Hantson, Martin Mackay, Saqib Islam and Vikas Sinha. View Institutional Ownership Trends for Alexion Pharmaceuticals.

Alexion Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, Aperio Group LLC, US Bancorp DE, Exxonmobil Investment Management Inc. TX, Sit Investment Associates Inc., Leavell Investment Management Inc., Oakbrook Investments LLC and Bremer Trust National Association. Company insiders that have sold Alexion Pharmaceuticals stock in the last year include Alvin S Parven, Carsten Thiel, Clare Carmichael, David Hallal, Edward Miller, Heidi L Wagner, John B Moriarty, Julie O'neill, Leonard Bell and Vikas Sinha. View Insider Buying and Selling for Alexion Pharmaceuticals.

Alexion Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Factory Mutual Insurance Co., First Quadrant L P CA, State Treasurer State of Michigan, Exane Asset Management, Mn Services Vermogensbeheer B.V., Peregrine Capital Management LLC and Assenagon Asset Management S.A.. Company insiders that have bought Alexion Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker and Ludwig Hantson. View Insider Buying and Selling for Alexion Pharmaceuticals.

Shares of Alexion Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Alexion Pharmaceuticals stock can currently be purchased for approximately $129.81.